ClinicalTrials.gg
CompletedNCT00087802Updated Apr 16, 2009

Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of gemcitabine/Eloxatin (GEMOX) and carboplatin/paclitaxel (CP) in Carcinoma, Non-Small-Cell Lung, sponsored by Sanofi. Completed at 70 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-04-16.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
383
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Carcinoma, Non-Small-Cell Lung by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Sanofi.

Enrollment
6th of 42
383 · median 69
Started
2004
with 2 others
Phase 3
8 of 47
none open now
Registered
6th of 47
by date

Among the 47 studies in Carcinoma, Non-Small-Cell Lung by Sanofi, this one is the 6th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2004, is one of 8 in phase 3, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 47 studies in Carcinoma, Non-Small-Cell Lung by Sanofi is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Carcinoma, Non-Small-Cell Lung by Sanofi, or all of them as a file.
02

Study summary

The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed, Stage IIIb or IV NSCLC, chemo or other systemic therapy naive
  • One (1) unidimensionally
  • Performance Status of 0 or 1, no peripheral neuropathy >Grade 1
  • Patients with clinically stable on a stable dose of (or no longer requiring) dexamethasone at registration will be eligible. Patients who have received cranial radiation for brain metastases must be at least 4 weeks from last radiation treatment.
  • Recovery in full from any previous surgical procedure
  • No history of an acute cardiac or CNS event within 6 months of entry or current clinical evidence of congestive heart failure or non-stable coronary artery disease

Exclusion criteria

Exclusion Criteria:

  • to any of the 4 study drugs
  • Concurrent immunotherapy or participation in any drug study within 4 weeks
  • Serious uncontrolled intercurrent medical or psychiatric illness and organ allograft
  • History of other within the last 5 years (except for squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix, or superficial transitional cell carcinoma of the bladder)
  • Patient is a pregnant or lactating female
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
383 participants (actual)

Study arms

  • Active comparator
    Stratum 1

    Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease). Randomization schedules will be produced for each stratum, and treatment allocation will be carried out centrally

    Drug: gemcitabine/Eloxatin (GEMOX)

  • Active comparator
    Stratum 2

    Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease).

    Drug: carboplatin/paclitaxel (CP)

Interventions

  • Druggemcitabine/Eloxatin (GEMOX)

    Drug page: Gemcitabine-oxaliplatin regimen

    GEMOX \[gemcitabine/Eloxatin™ (Oxaliplatin) - 21 day cycle\] Gemcitabine 1000 mg/m2 will be administered over 30 minutes on Days 1 and 8 and Eloxatin™ 130 mg/m2 will be administered over 2 hours on Day 1, after gemcitabine administration, every 21 days \[3-week cycle\]

  • Drugcarboplatin/paclitaxel (CP)

    CP \[carboplatin/paclitaxel - 21 day cycle\] o Paclitaxel 225 mg/m2 will be administered over 3 hours on Day 1 followed by carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 6.0 over 30-60 minutes on Day 1 every 21 days \[3-week cycle\]

06

What researchers measure

Primary outcomes

  1. To determine the relative efficacy, safety and clinical benefit of the GEMOX regimen compared to the standard combination regimen of CP as first-line treatment of Stage IIIB and IV NSCLC

    Time frame: 22 months

07

Study locations

70 sites
  • Birmingham Hematology and Oncology Associates, LLC
    Birmingham, Alabama 35235, United States
  • Birmingham Hematology and Oncology Associates
    Birmingham, Alabama 35235, United States
  • Hematology Oncology Associates
    Phoenix, Arizona 85012, United States
  • Northern Arizona Hematology & Oncology Associates
    Sedona, Arizona 86336, United States
  • Arizona Oncology Associates - Hematology Oncology Physicians
    Tucson, Arizona 85704, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34652, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • South Florida Oncology & Hematology Consultants
    Plantation, Florida 33324, United States
  • Hematology Oncology Associates of Illinois
    Chicago, Illinois 60611, United States
  • Northwest Medical Specialists, PC
    Niles, Illinois 60714, United States
  • Hematology Oncology Associates of Illinois
    Skokie, Illinois 60077, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Oncology Associates of Cedar Rapids
    Cedar Rapids, Iowa 52403, United States
  • Kansas City Oncology and Hematology Group
    Overland Park, Kansas 66210, United States
  • Maryland Oncology Hematology, P.A.
    Columbia, Maryland 21044, United States
  • Berkshire Hematology Oncology, PC
    Pittsfield, Massachusetts 01201, United States
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55404, United States
  • Minnesota Oncology Hematology
    Minneapolis, Minnesota 55404, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Arch Medical Services, Inc.
    St. Louis, Missouri 63141, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89109, United States
  • New Mexico Cancer Care Associates
    Santa Fe, New Mexico 87505, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12208, United States
  • New York Oncology Hematology
    Latham, New York 12110, United States
  • New York Oncology Hematology, P.C.
    Rexford, New York 12148, United States
  • Interlakes Oncology & Hematology, P.C.
    Rochester, New York 14623, United States
  • Raleigh Hematology Oncology Clinic
    Cary, North Carolina 27511, United States
  • Piedmont Hematology Oncology Associates, PLLC.
    Winston-Salem, North Carolina 27103, United States
  • Dayton Oncology & Hematology, P.A.
    Kettering, Ohio 45409, United States
  • Cancer Care Associates
    Oklahoma City, Oklahoma 73120, United States
  • Cancer Care Associates
    Tulsa, Oklahoma 74136-1902, United States
  • Willamette Valley Cancer Center
    Eugene, Oregon 97401, United States
  • Cancer Centers of the Carolinas
    Seneca, South Carolina 29672, United States
  • Texas Cancer Center - Abilene
    Abilene, Texas 79606, United States
  • Texas Oncology, P.A.
    Arlington, Texas 76012, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • Mamie McFaddin Ward Cancer Center
    Beaumont, Texas 77702-1449, United States
  • Texas Oncology, P.A.
    Bedford, Texas 76022, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230-2510, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75231, United States
  • The Texas Cancer Center
    Dallas, Texas 75237, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
  • Texas Cancer Center - Denton
    Denton, Texas 76210, United States
  • El Paso Cancer Treatment Ctr-East
    El Paso, Texas 79915, United States
  • Texas Oncology, P.A.
    Fort Worth, Texas 76104, United States
  • San Antonio Tumor and Blood Clinic
    Fredericksburg, Texas 78624, United States
  • Texas Oncology, P.A.
    Garland, Texas 75042-5788, United States
  • Texas Oncology, P.A.
    Houston, Texas 77024, United States
  • Texas Oncology, P.A.
    Irving, Texas 75061-2244, United States
  • Lake Vista Cancer Center
    Lewisville, Texas 75067, United States
  • Longview Cancer Center
    Longview, Texas 75601, United States
  • South Texas Cancer Center - McAllen
    McAllen, Texas 78503-1298, United States
  • Texas Cancer Center of Mesquite
    Mesquite, Texas 75150, United States
  • Allison Cancer Center
    Midland, Texas 79701-5946, United States
  • West Texas Cancer Center
    Odessa, Texas 79761, United States
  • Paris Regional Cancer Center
    Paris, Texas 75460, United States
  • Hematology Oncology Associates of South Texas
    San Antonio, Texas 78229, United States
  • Texas Cancer Center - Sherman
    Sherman, Texas 75090-0504, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Waco Cancer Care and Research Center
    Waco, Texas 76712, United States
  • Deke Slayton Cancer Center
    Webster, Texas 77598, United States
  • Fairfax Northern Virginia Hematology Oncology, PC
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Oncology & Hematology Associates of Southwest Virginia, Inc.
    Salem, Virginia 24153, United States
  • Puget Sound Cancer Centers
    Edmonds, Washington 98026, United States
  • Puget Sound Cancer Centers
    Seattle, Washington 98133, United States
  • Cancer Care Northwest
    Spokane, Washington 99218, United States
  • Northwest Cancer Specialists, P.C.
    Vancouver, Washington 98684, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004 and a primary completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2004
First posted
Jul 16, 2004
Start
Mar 2004
Primary completionActual
May 2007
Last update
Apr 16, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00087802
Lead sponsor
Sanofi
First posted
Jul 16, 2004
Start date
Mar 2004
Primary completion
May 2007
Last update
Apr 16, 2009

Study contacts

Yasir Nagarwala, MD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine-oxaliplatin regimen

Start the discussion